Oslo, Norway, May 05, 2021 - The Annual General Meeting of Vaccibody AS was held
May 5, 2021. All proposed resolutions on the agenda were approved in accordance
with the notice for the meeting, which were published on April 28, 2021.
Please find the minutes of the meeting enclosed.
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies. The Company
develops vaccines for the treatment cancer and infectious diseases. Vaccibody's
vaccine technology specifically targets antigens to Antigen Presenting Cells,
which are essential for inducing rapid, strong and long-lasting antigen-specific
immune responses and elicit efficacious clinical responses. Its lead product
candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively
outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment
of melanoma, lung-, head and neck, renal-, and bladder cancer